This overview explains how proteomics sample preparation underpins mass spectrometry performance. It details best practices ...
Comprehensive residue-level mapping of amyloid-beta recognition reveals how sequence variants, post-translational ...
BACKGROUND: The disruption of the blood–brain barrier (BBB) is a central pathogenic event in many central nervous system disorders. However, the mechanisms regulating BBB function remain incompletely ...
Risk prediction has been used in the primary prevention of cardiovascular disease for >3 decades. Contemporary cardiovascular risk assessment relies on multivariable models, which integrate ...
BD (Becton, Dickinson and Company) , a leading global medical technology company, today announced results for its fiscal 2026 first quarter, which ended December 31, 2025. "We delivered stronger?than?
Revenue of $5.3 billion increased 1.6% as reported, 0.4% FXN New BD revenue increased 2.5% FXN GAAP and adjusted diluted EPS of $1.34 and $2.91, respectively Combination ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results